Volume 11, Number 8—August 2005
Research
Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*
Table 3
Longitudinal GEE models*
| Drug | FQ-R P. aeruginosa |
MRSA |
||
|---|---|---|---|---|
| Coefficient | p value | Coefficient | p value | |
| Total FQ | ||||
| Previous year's resistance | 0.875 | <0.001 | 0.804 | <0.001 |
| Total FQ use | 0.002 | 0.883 | 0.025 | 0.155 |
| Time | -0.312 | 0.554 | 1.04 | 0.040 |
| Constant | 6.75 | 0.001 | 4.61 | 0.058 |
| Levofloxacin | ||||
| Previous year's resistance | 0.868 | <0.001 | 0.818 | <0.001 |
| Levofloxacin use | 0.005 | 0.548 | 0.012 | 0.033 |
| Time | -0.317 | 0.579 | 1.04 | 0.041 |
| Constant | 6.78 | 0.001 | 6.38 | 0.001 |
| Ciprofloxacin | ||||
| Previous year's resistance | 0.866 | <0.001 | 0.845 | <0.001 |
| Ciprofloxacin use | -0.018 | 0.226 | -0.004 | 0.848 |
| Time | -0.393 | 0.475 | 0.991 | 0.079 |
| Constant | 8.185 | <0.001 | 6.55 | 0.033 |
*Association of fluoroquinolone and pathogen resistance over time controlling for prior year resistance. GEE, generalized estimating equations; FQ-R P. aeruginosa, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential